12(s)-hete receptor blockers
CA 2303935 A1 · Owner: City Of Hope · Inventors: Nadler, Jerry L.; Natarajan, Rama Devi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The 12-lipoxygenase product, 12(S)-HETE mediates hyperproliferative and , hyperplastic responses seen in atherosclerosis diabetes, Parkinson's disease, Alzheimer's stroke-induced nerve damage and cancer. 12-HETE also mediates inflammation and cell death in some cell systems particularly B-islet cells , of the pancreas. The present invention involves amelioration of disease states mediated by 12(S)-HETE by blocking specific 12(S)-HETE receptors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 14, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 14, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 14, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.